A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

Trial Details

NCT ID
NCT05800665
Phase
PHASE1
Sponsor
Genentech, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • RO7656594
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Orlando, Florida, United States|28.53834,-81.37924
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Nashville, Texas, United States|30.82583,-96.65278

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
  • Metastatic prostate adenocarcinoma without small-cell carcinoma or neuroendocrine features.
  • Prior therapy with a second-generation androgen receptor (AR)-targeted therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide).
  • Prior therapy with a taxane regimen or are considered ineligible for treatment with a taxane regimen or have refused treatment with a taxane regime…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →